Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Cancer Monoclonal Antibody Market Cancer rates continue to rise, especially in aging populations and areas affected by pollution and lifest ...